Brokerages Anticipate Teva Pharmaceutical Industries Ltd (NYSE:TEVA) to Post $0.61 Earnings Per Share

Wall Street brokerages expect that Teva Pharmaceutical Industries Ltd (NYSE:TEVA) will post earnings per share (EPS) of $0.61 for the current quarter, according to Zacks. Seven analysts have provided estimates for Teva Pharmaceutical Industries’ earnings. The lowest EPS estimate is $0.56 and the highest is $0.67. Teva Pharmaceutical Industries posted earnings of $0.53 per share in the same quarter last year, which would suggest a positive year over year growth rate of 15.1%. The firm is scheduled to issue its next quarterly earnings report on Wednesday, February 12th.

On average, analysts expect that Teva Pharmaceutical Industries will report full-year earnings of $2.38 per share for the current financial year, with EPS estimates ranging from $2.25 to $2.48. For the next year, analysts expect that the company will report earnings of $2.52 per share, with EPS estimates ranging from $2.36 to $2.76. Zacks’ earnings per share averages are an average based on a survey of research firms that follow Teva Pharmaceutical Industries.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings data on Wednesday, August 7th. The company reported $0.57 EPS for the quarter, topping analysts’ consensus estimates of $0.55 by $0.02. Teva Pharmaceutical Industries had a negative net margin of 21.94% and a positive return on equity of 16.04%. The firm had revenue of $4.34 billion for the quarter, compared to analyst estimates of $4.25 billion. During the same quarter in the previous year, the business posted $0.78 EPS. The firm’s revenue was down 7.7% compared to the same quarter last year.

TEVA has been the topic of a number of recent analyst reports. Wolfe Research initiated coverage on shares of Teva Pharmaceutical Industries in a report on Friday, July 19th. They issued a “peer perform” rating and a $9.00 price objective on the stock. Gabelli upgraded shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a report on Wednesday, October 16th. Raymond James cut their price objective on shares of Teva Pharmaceutical Industries from $22.00 to $15.00 and set an “outperform” rating on the stock in a report on Thursday, August 8th. JPMorgan Chase & Co. cut their price objective on shares of Teva Pharmaceutical Industries from $9.00 to $7.00 and set an “underweight” rating on the stock in a report on Friday, September 6th. Finally, Royal Bank of Canada restated a “hold” rating and issued a $10.00 target price on shares of Teva Pharmaceutical Industries in a research note on Thursday, August 8th. Six investment analysts have rated the stock with a sell rating, thirteen have given a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. Teva Pharmaceutical Industries presently has an average rating of “Hold” and an average target price of $10.78.

TEVA stock traded up $0.83 during trading on Tuesday, reaching $9.30. The stock had a trading volume of 34,192,717 shares, compared to its average volume of 16,922,125. Teva Pharmaceutical Industries has a 1-year low of $6.07 and a 1-year high of $23.97. The company has a current ratio of 0.96, a quick ratio of 0.62 and a debt-to-equity ratio of 1.73. The company has a market capitalization of $9.32 billion, a P/E ratio of 3.32, a PEG ratio of 0.89 and a beta of 1.73. The firm has a fifty day moving average price of $7.51 and a 200 day moving average price of $8.90.

Several institutional investors have recently modified their holdings of the company. DNB Asset Management AS raised its stake in Teva Pharmaceutical Industries by 10.9% during the second quarter. DNB Asset Management AS now owns 85,262 shares of the company’s stock worth $787,000 after acquiring an additional 8,379 shares during the period. Sanders Morris Harris LLC acquired a new stake in Teva Pharmaceutical Industries during the second quarter worth about $76,000. Exane Derivatives raised its stake in Teva Pharmaceutical Industries by 470.2% during the second quarter. Exane Derivatives now owns 53,093 shares of the company’s stock worth $490,000 after acquiring an additional 43,782 shares during the period. Xact Kapitalforvaltning AB raised its stake in Teva Pharmaceutical Industries by 37.2% during the second quarter. Xact Kapitalforvaltning AB now owns 39,100 shares of the company’s stock worth $361,000 after acquiring an additional 10,600 shares during the period. Finally, Bridge Creek Capital Management LLC raised its stake in Teva Pharmaceutical Industries by 9.3% during the second quarter. Bridge Creek Capital Management LLC now owns 30,425 shares of the company’s stock worth $281,000 after acquiring an additional 2,600 shares during the period. Institutional investors and hedge funds own 58.21% of the company’s stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Recommended Story: What does a hold rating mean?

Get a free copy of the Zacks research report on Teva Pharmaceutical Industries (TEVA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.